BeiGene
BGNE
#963
Rank
โ‚ฌ19.32 B
Marketcap
170,29ย โ‚ฌ
Share price
1.02%
Change (1 day)
5.83%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

BeiGene (BGNE) - Total debt

Total debt on the balance sheet as of September 2024 : โ‚ฌ1.06 Billion

According to BeiGene 's latest financial reports the company's total debt is โ‚ฌ1.06 Billion. A companyโ€™s total debt is the sum of all current and non-current debts.

BeiGene - Total debt on balance sheet (from 2014 to 2024)

Total debt by year

Year Total debt Change
2023-12-31โ‚ฌ0.84 B51.27%
2022-12-31โ‚ฌ0.55 B-9.31%
2021-12-31โ‚ฌ0.61 B34.25%
2020-12-31โ‚ฌ0.45 B84.54%
2019-12-31โ‚ฌ0.24 B42.75%
2018-12-31โ‚ฌ0.17 B26.33%
2017-12-31โ‚ฌ0.13 B735.44%
2016-12-31โ‚ฌ16.43 M-13.56%
2015-12-31โ‚ฌ19.01 M67.08%
2014-12-31โ‚ฌ11.37 M-42.58%
2013-12-31โ‚ฌ19.81 M

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
N/AN/A๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ0.49 B-53.49%๐Ÿ‡บ๐Ÿ‡ธ USA